Frequently Asked Questions

Questions about DUPIXENT?
We can help.

We’re committed to answering questions you may have about DUPIXENT.
If you don’t find an answer to a question or would like more information,
please contact a rep.

DUPIXENT Basics

DUPIXENT has a unique mechanism of action in asthma. It is the first and only dual inhibitor of IL-4 and IL-13 signaling, inhibiting two key sources of Type 2 inflammation in asthma. IL-4 and IL-13 signaling impact Type 2 inflammation both locally and systemically. DUPIXENT is not an immunosuppressant. The mechanism of dupilumab action in asthma has not been definitively established.1-3

Watch a video on how
DUPIXENT targets IL-4
and IL-13 signaling

DUPIXENT is indicated as an add‑on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate‑to‑severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.1

See EXAMPLES OF APPROPRIATE PATIENT TYPES FOR DUPIXENT

Type 2 inflammation is present in up to 84% of adult asthma patients and can be both local and systemic. DUPIXENT targets both IL-4 and IL-13 signaling, inhibiting two key sources of Type 2 inflammation in asthma. The mechanism of dupilumab action in asthma has not been definitively established.1-5

DUPIXENT is indicated as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.1

Learn more about patients who may be affected by Type 2 inflammation

DUPIXENT is the first and only dual inhibitor of IL-4 and IL-13 signaling. It is the only biologic indicated for OCSdependent asthma patients. The mechanism of dupilumab action in asthma has not been definitively established.1

WATCH A VIDEO ON THE UNIQUE MOA OF DUPIXENT

Yes. DUPIXENT treatment decreased FeNO (up to 35% reduction from baseline by Week 2a) and circulating concentrations of eotaxin-3, total IgE (up to 83% reduction from baseline at Week 96b), allergen-specific IgE, TARC, and periostin in asthma subjects relative to placebo. DUPIXENT decreased these markers of Type 2 inflammation and sustained the effects throughout treatment. In addition, there was an impact on eosinophil activation and trafficking (up to 35% median percent reduction from baseline at Week 96b). The mechanism of dupilumab action in asthma has not been definitively established.1,6‑11

a DRI12544.

b TRAVERSE OLE.

Explore the role these biomarkers have in the pathogenesis of asthma

In addition to moderate-to-severe asthma, DUPIXENT is indicated in 2 other disease states.1

LEARN MORE

DUPIXENT Clinical Data

DUPIXENT offers rapid breathing relief patients can feel as early as Week 2. Approximately 72% of the total FEV1 improvement (470 mL improvement at Week 52 compared to baseline FEV1 of 1.78 L) was seen at Week 2 in patients in QUEST with baseline blood EOS ≥300 cells/μL taking DUPIXENT 200 mg + SOC (n=264) (secondary endpoint).1,12

320 mL improvement from baseline in pre-bronchodilator FEV1 at Week 12 with DUPIXENT 200 mg + SOC (n=631) vs 180 mL with placebo + SOC (n=317) (LSM difference: 140 mL [95% CI: 80, 190 mL]) (QUEST, ITT population, primary endpoint).1

In QUEST, a significant difference from placebo + SOC was not observed at 12 weeks in change in pre-bronchodilator FEV1 in patients with baseline blood EOS ≥150 to <300 cells/μL taking DUPIXENT 300 mg + SOC and in patients with baseline blood EOS <150 cells/μL taking DUPIXENT 200 mg or 300 mg + SOC.1

Explore the lung function data

Patients with baseline blood EOS ≥300 cells/μL in QUEST experienced sustained breathing relief at Week 52: a 470 mL improvement from baseline in pre-bronchodilator FEV1 with DUPIXENT 200 mg + SOC (n=264) vs 170 mL with placebo + SOC (n=148) (secondary endpoint).1,12

Explore the lung function data

DUPIXENT reduced severe exacerbations by up to 81% in subjects with EOS ≥300 cells/μL with DUPIXENT 300 mg + SOC (n=64) vs placebo + SOC (n=68) (0.20 vs 1.04; rate ratio: 0.19 [95% CI: 0.07, 0.56]) (secondary endpoint) in DRI12544.

In addition, DUPIXENT demonstrated a 60% reduction in severe exacerbations in subjects with EOS ≥150 cells/µL with DUPIXENT 300 mg + SOC (n=452) vs placebo + SOC (n=237) (rate ratio: 0.40 [95% CI: 0.31, 0.53]) (secondary endpoint) in QUEST.

DUPIXENT also reduced severe exacerbations by 46% in patients with no biomarker requirement (ITT population) with DUPIXENT 300 mg + SOC (n=633) vs placebo + SOC (n=321) (rate ratio: 0.54 [95% CI: 0.43, 0.68]) (primary endpoint) in QUEST.

No statistically significant differences were observed during the 52-week treatment period in patients with baseline blood EOS <150 cells/μL taking DUPIXENT 200 mg or 300 mg + SOC and in the ≥150 to <300 cells/μL EOS subgroup treated with DUPIXENT 200 mg + SOC vs matching placebo + SOC in QUEST.1,10

View the exacerbation data

In VENTURE in the ITT population, 86% of OCS-dependent asthma patients reduced or eliminated their OCS dose at Week 24 with DUPIXENT 300 mg + SOC (n=103) vs 68% with placebo + SOC (n=107). Overall, more than half of patients receiving DUPIXENT 300 mg + SOC (n=103) in the ITT population in VENTURE completely eliminated their OCS use at Week 24 vs 29% with placebo + SOC (n=107) (secondary endpoints).

70% significant reduction in OCS dose (median 100%) from baseline at Week 24 with DUPIXENT 300 mg + SOC (n=103) (95% CI: 60%, 80%) vs 42% (median 50%) with placebo + SOC (n=107) (primary endpoint).1,13

Learn more about how DUPIXENT MAY IMPACT OCS use

DUPIXENT simultaneously improved asthma control (ie, reducing severe exacerbations, improving lung function) while reducing or eliminating steroid use in the ITT population at Week 24 (VENTURE, no biomarker requirement, secondary endpoints).

  • 86% of OCS-dependent asthma patients reduced or eliminated their OCS dose at Week 24 with DUPIXENT 300 mg + SOC (n=103) vs 68% with placebo + SOC (n=107)
    • 70% significant reduction in OCS dose (median 100%) from baseline at Week 24 with DUPIXENT 300 mg + SOC (n=103) (95% CI: 60%, 80%) vs 42% (median 50%) with placebo + SOC (n=107) (primary endpoint)
  • 59% reduction in severe exacerbations at Week 24 with DUPIXENT 300 mg + SOC (n=103) vs placebo + SOC (n=107) (0.65 vs 1.60; rate ratio: 0.41 [95% CI: 0.26, 0.63])
  • 220 mL improvement in lung function at Week 24 with DUPIXENT 300 mg + SOC (n=103) vs 10 mL with placebo + SOC (n=107) (LSM difference: 220 mL [95% CI: 90, 340 mL])1,13

Learn more about how DUPIXENT may impact OCS use

The most common adverse reactions from the DUPIXENT asthma trials were injection site reactions, oropharyngeal pain, and eosinophilia. These adverse reactions occurred in ≥1% of patients receiving DUPIXENT + SOC and at a higher rate than in patients receiving placebo + SOC in DRI12544 and QUEST (6-month safety pool).1

View the Full Safety Data

View the Full Safety Data FOR PEDIATRIC PATIENTS (6-11 YEARS)

Subjects enrolled in DRI12544 and QUEST were required to have a history of at least 1 severe asthma exacerbation in the year prior to trial entry. A severe asthma exacerbation was defined as deterioration of asthma requiring the use of systemic corticosteroids for at least 3 days or asthma-related hospitalization or emergency department visit requiring systemic corticosteroids.1

Subjects enrolled in DRI12544 and QUEST were receiving the SOC for their moderate-to-severe asthma. Those enrolled in VENTURE required dependence on daily OCS in addition to regular use of high-dose ICS plus a minimum of 1 and up to 2 additional controller medications as SOC for their asthma. In all 3 trials, enrollment was unrestricted by minimum baseline blood eosinophil count. In QUEST and VENTURE, subjects with screening blood eosinophil levels >1500 cells/μL (<1.3%) were excluded.1,13

Subjects enrolled in the 52-week pediatric trial were pediatric patients (6-11 years), with uncontrolled moderate-to-severe asthma on an SOC of medium-dose ICS with a second controller or high-dose ICS with or without a second controller. Patients were evaluated in 2 prespecified populations: blood EOS ≥300 cells/μL and blood EOS ≥150 cells/μL or FeNO ≥20 ppb.14

View the full study designs View the full study DESIGN FOR PEDIATRIC PATIENTS (6-11 YEARS)

Using DUPIXENT

DUPIXENT is an injectable medicine that is administered by subcutaneous injection. DUPIXENT is intended for use under the guidance of a healthcare provider. However, patients 12 years of age and older may self‑inject DUPIXENT after receiving training in subcutaneous injection technique using the pre‑filled syringe or pen. In pediatric patients 12 years of age and older, it is recommended that DUPIXENT be administered under the supervision of an adult. The DUPIXENT pre‑filled syringe should be given by a caregiver in pediatric patients (6‑11 years).1

LEARN MORE ABOUT DOSING INSTRUCTIONS, SCHEDULES, AND RECOMMENDATIONS

If your patient is 12+ years and has moderate-to-severe asthma with an eosinophilic phenotype, DUPIXENT is available in 200 mg and 300 mg doses. The 200 mg treatment, given every 2 weeks, has an initial loading dose of 400 mg (2 x 200 mg pre-filled pens or syringes), and the 300 mg treatment, given every 2 weeks, has an initial loading dose of 600 mg (2 x 300 mg pre-filled pens or syringes).1

If your patient is 12+ years and has OCS-dependent asthma or comorbid moderate-to-severe atopic dermatitis or is an adult with comorbid chronic rhinosinusitis with nasal polyposis, the recommended dose is an initial loading dose of 600 mg (2 x 300 mg pre-filled pens or syringes) followed by 300 mg given every 2 weeks.1

If your patient is aged (6-11 years) with uncontrolled asthma for which DUPIXENT is indicated, the dosing is weight-based. For pediatric patients 15 kg to less than 30 kg,c the recommended dose is 100 mg given every 2 weeks or 300 mg given every 4 weeks via pre-filled syringe. For pediatric patients 30 kg or more,d the recommended dose is 200 mg given every 2 weeks via pre-filled syringe. For pediatric patients (6-11 years) with asthma and comorbid moderate-to-severe atopic dermatitis, follow the recommended dosage for atopic dermatitis, which includes an initial loading dose.1

c 15 kg is equal to 33 lb

d 30 kg is equal to 66 lb.

LEARN MORE ABOUT DOSING INSTRUCTIONS, SCHEDULES, AND RECOMMENDATIONS

Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating treatment with DUPIXENT. You should avoid the use of live vaccines in patients being treated with DUPIXENT. It is unknown if administration of live vaccines during DUPIXENT treatment will impact the efficacy or safety of these vaccines.

Immune responses to non-live vaccines were assessed in a study in which adult subjects with atopic dermatitis were treated once weekly for 16 weeks with 300 mg of dupilumab (twice the recommended dosing frequency). After 12 weeks of DUPIXENT administration, subjects were vaccinated with a Tdap vaccine (Adacel®) and a meningococcal polysaccharide vaccine (Menomune®). Antibody responses to tetanus toxoid and serogroup C meningococcal polysaccharide were assessed 4 weeks later. Antibody responses to both tetanus vaccine and meningococcal polysaccharide vaccine were similar in dupilumab-treated and placebo-treated subjects. Immune responses to the other active components of the Adacel and Menomune vaccines were not assessed.1

The pre-filled syringe and the pre-filled pen each come with their own set of specific instructions and guidelines for administration. After choosing your preferred method of treatment, it is important to provide proper training to patients and/or caregivers on the preparation and administration of DUPIXENT prior to use to ensure each step is followed correctly. In pediatric patients 12 years of age and older, it is recommended that DUPIXENT be administered under the supervision of an adult.1

In pediatric patients (6-11 years), a caregiver may inject a child with DUPIXENT after training in subcutaneous injection technique using the pre-filled syringe. Provide proper training to caregivers on the preparation and administration of DUPIXENT prior to use according to the Instructions for Use.1

Advise patients to follow sharps disposal recommendations after administration of DUPIXENT. Patients and/or caregivers should read the appropriate Instructions for Use prior to injecting.1

Download the full Instructions for Use below.

Pre-filled Pen Instructions for Use – 200 mg
Pre-filled Pen Instructions for Use – 300 mg Pre-filled Syringe Instructions for Use – 100 mg Pre-filled Syringe Instructions for Use – 200 mg Pre-filled Syringe Instructions for Use – 300 mg

If a dose is missed, instruct the patient to administer the injection within 7 days from the missed dose and then resume the patient’s original schedule. If the missed dose is not administered within 7 days, instruct the patient to wait until the next dose on the original schedule.1

LEARN MORE ABOUT DOSING INSTRUCTIONS, SCHEDULES, AND RECOMMENDATIONS

DUPIXENT should be refrigerated at 36 °F to 46 °F (2 °C to 8 °C) in the original carton to protect from light. However, before DUPIXENT is injected, it must be removed from the refrigerator and allowed to reach room temperature without removing the needle cap.

  • For the 300 mg/2 mL pre-filled pen or syringe, allow 45 minutes for DUPIXENT to reach room temperature1
  • For the 200 mg/1.14 mL pre-filled pen or syringe, allow 30 minutes for DUPIXENT to reach room temperature1
  • For the 100 mg/0.67 mL pre-filled syringe, allow 30 minutes for DUPIXENT to reach room temperature1
SEE INFORMATION ON PREPARATION FOR USE, STORAGE, AND HANDLING of DUPIXENT

DUPIXENT Access and Support

DUPIXENT MyWay is a patient support program that can help enable access to DUPIXENT through benefits verification and assistance navigating the insurance process. It also offers financial assistance for eligible patients, one-on-one nursing support, and more.

LEARN MORE ABOUT THE SUPPORT OFFERED BY DUPIXENT MyWay

When filling out the DUPIXENT MyWay Enrollment Form, both you and your patient will be required to supply information, such as the patient’s insurance, diagnosis, and prescription. You can email or print the enrollment forms below.

DUPIXENT MyWay
ENROLLMENT FORMS

FOR ALLERGISTS
English Enrollment Form
Spanish Enrollment Form
FOR ENT SPECIALISTS/PULMONOLOGISTS
English Enrollment Form
Spanish Enrollment Form

Overall, ~98% of commercially insured patients nationally are covered for DUPIXENT (MMIT Lives as of November 2021). Coverage varies by type and plan.15

With the DUPIXENT formulary status tool, you can see which insurance plans offer coverage for DUPIXENT in your area. Contact the health plan or DUPIXENT MyWay to verify coverage for a specific patient.

USE THE DUPIXENT FORMULARY STATUS TOOL

Patients may be eligible for the DUPIXENT MyWay Copay Card if:

  • They have commercial insurance
  • They have a DUPIXENT prescription for an FDA-approved condition
  • They are a resident of the 50 United States, the District of Columbia, Puerto Rico, Guam, or the USVI
  • The patient or caregiver is aged 18 years or older

Eligible patients covered by commercial health insurance may pay as little as a $0e copay per fill of DUPIXENT (maximum of $13,000 per patient per calendar year).

eApproval is not guaranteed. Program has an annual maximum of $13,000. THIS IS NOT INSURANCE. Not valid for prescriptions paid, in whole or in part, by Medicaid, Medicare, VA, DOD, TRICARE, or other federal or state programs including any state pharmaceutical assistance programs. This program is not valid where prohibited by law, taxed or restricted. DUPIXENT MyWay reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Any savings provided by the program may vary depending on patients' out-of-pocket costs. The program is intended to help patients afford DUPIXENT. Patients may have insurance plans that attempt to dilute the impact of the assistance available under the program. In those situations, the program may change its terms. Additional terms and conditions apply.

COPAY CARD ONLINE SIGN-UP

EOS, eosinophils; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; ITT, intention-to-treat; LSM, least squares mean; OCS, oral corticosteroid; SOC, standard of care; TARC, thymus and activation-regulated chemokine.

References:

  1. DUPIXENT Prescribing Information.
  2. Corren J. Role of interleukin-13 in asthma. Curr Allergy Asthma Rep. 2013;13(5):415-420.
  3. Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50.
  4. Seys SF, Scheers H, Van den Brande P, et al. Cluster analysis of sputum cytokine-high profiles reveals diversity in T(h)2-high asthma patients. Respir Res. 2017;18(1):39. doi:10.1186/s12931-017-0524-y
  5. Jackson DJ, Aljamil N, Roxas C, et al. The ‘T2-low’ asthma phenotype: could it just be T2-high asthma treated with corticosteroids? Thorax. 2018;73(suppl 4):A124-A125. Abstract P48.
  6. Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486-2496.
  7. Robinson D, Humbert M, Buhl R, et al. Revisiting type 2-high and type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. 2017;47(2):161-175.
  8. Ravensberg AJ, Ricciardolo FLM, van Schadewijk A, et al. Eotaxin-2 and eotaxin-3 expression is associated with persistent eosinophilic bronchial inflammation in patients with asthma after allergen challenge. J Allergy Clin Immunol. 2005;115(4):779-785.
  9. Data on file, Sanofi US. LIBERTY ASTHMA TRAVERSE CSR, 2020.
  10. Data on file, Sanofi US. QUEST CSR, 2017.
  11. Wechsler ME, Ford LB, Maspero JF, et al. Dupilumab long-term safety and efficacy in patients with asthma: LIBERTY ASTHMA TRAVERSE. Poster presented at: 30th International Congress of the European Respiratory Society; September 7-9, 2020.
  12. Santanello NC, Zhang J, Seidenberg B, Reiss TF, Barber BL. What are minimal important changes for asthma measures in a clinical trial? Eur Respir J. 1999;14(1):23-27.
  13. Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475-2485.
  14. Data on file, Sanofi US. LIBERTY ASTHMA VOYAGE CSR, 2020.
  15. The Dedham Group Quality of Access Tracking Report. November 2021.

Important Safety
Information and Indications

CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT compared to those who received placebo, with conjunctivitis being the most frequently reported eye disorder. Conjunctivitis also occurred more frequently in chronic rhinosinusitis with nasal polyposis subjects who received DUPIXENT compared to those who received placebo. Conjunctivitis and keratitis have been reported with DUPIXENT in postmarketing settings, predominantly in atopic dermatitis patients. Some patients reported visual disturbances (e.g. blurred vision) associated with conjunctivitis or keratitis. Advise patients to report new onset or worsening eye symptoms to their healthcare provider. Consider ophthalmological examination for patients who develop conjunctivitis that does not resolve following standard treatment or signs and symptoms suggestive of keratitis, as appropriate.

Eosinophilic Conditions: Patients being treated for asthma may present with serious systemic eosinophilia sometimes presenting with clinical features of eosinophilic pneumonia or vasculitis consistent with eosinophilic granulomatosis with polyangiitis (EGPA), conditions which are often treated with systemic corticosteroid therapy. These events may be associated with the reduction of oral corticosteroid therapy. Healthcare providers should be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients with eosinophilia. Cases of eosinophilic pneumonia were reported in adult subjects who participated in the asthma development program and cases of vasculitis consistent with EGPA have been reported with DUPIXENT in adult subjects who participated in the asthma development program as well as in adult subjects with co-morbid asthma in the CRSwNP development program. A causal association between DUPIXENT and these conditions has not been established.

Acute Asthma Symptoms or Deteriorating Disease: Do not use DUPIXENT to treat acute asthma symptoms, acute exacerbations, acute bronchospasm or status asthmaticus. Patients should seek medical advice if their asthma remains uncontrolled or worsens after initiation of DUPIXENT.

Risk Associated with Abrupt Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation of DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a healthcare provider. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Patients with Co-morbid Asthma: Advise patients with atopic dermatitis or CRSwNP who have co-morbid asthma not to adjust or stop their asthma treatments without consultation with their physicians.

Arthralgia: Arthralgia has been reported with the use of DUPIXENT with some patients reporting gait disturbances or decreased mobility associated with joint symptoms; some cases resulted in hospitalization. Advise patients to report new onset or worsening joint symptoms. If symptoms persist or worsen, consider rheumatological evaluation and/or discontinuation of DUPIXENT.

Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves. Helminth infections (5 cases of enterobiasis and 1 case of ascariasis) were reported in pediatric patients 6 to 11 years old in the pediatric asthma development program.

Vaccinations: Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating DUPIXENT. Avoid use of live vaccines in patients treated with DUPIXENT.

ADVERSE REACTIONS:

  • Atopic dermatitis: The most common adverse reactions (incidence ≥1% at Week 16) in adult patients are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, and dry eye. The safety profile in children and adolescents through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT in adolescents and children observed through Week 52 was consistent with that seen in adults with atopic dermatitis.
  • Asthma: The most common adverse reactions (incidence ≥1%) are injection site reactions, oropharyngeal pain, and eosinophilia.
  • Chronic rhinosinusitis with nasal polyposis: The most common adverse reactions (incidence ≥1%) are injection site reactions, eosinophilia, insomnia, toothache, gastritis, arthralgia, and conjunctivitis.

USE IN SPECIFIC POPULATIONS

  • Pregnancy: A pregnancy exposure registry monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. To enroll or obtain information call 1‑877‑311‑8972 or go to https://mothertobaby.org/ongoing-study/dupixent/. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
  • Lactation: There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

Please see accompanying full Prescribing Information.

Indications

Asthma: DUPIXENT is indicated as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.

Chronic rhinosinusitis with nasal polyposis (CRSwNP): DUPIXENT is indicated as an add-on maintenance treatment in adult patients with inadequately controlled CRSwNP.

Atopic Dermatitis: DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.